Abstract

AIM: To investigate the correlation between expression of phosphatase and tensin homolog (PTEN) and cetuximab effects in colorectal cancer.

METHODS: We searched PubMed, EMBASE and ASCO to identify eligible studies. Finally, 8 randomized control studies were included in the meta-analysis. STATA 10.0 Software was used to investigate heterogeneity among individual studies and to summarize all the studies. Risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the strength of the association.

RESULTS: Compared with 20 of 266 patients with loss of PTEN, 206 of 496 patients with intact PTEN protein expression had a better objective response rate to cetuximab-based therapy (RR, 4.75; 95% CI, 2.59-8.72; \( P < 0.001 \)). PTEN positivity was associated with better progression-free survival (PFS) (HR, 0.675; 95% CI, 0.440-1.138; \( P = 0.154 \)) but not with better overall survival (OS) (HR, 0.943; 95% CI, 0.646-1.377; \( P = 0.761 \)).

CONCLUSION: Expression of PTEN is related to the effect of cetuximab in colorectal cancer patients and should be considered in treatment with cetuximab.

© 2012 Baishideng. All rights reserved.

Key words: Phosphatase and tensin homolog; Cetuximab; Colorectal cancer; Prognosis; Meta-analysis

INTRODUCTION

Colorectal cancer (CRC) is the fourth common malignancy and the second leading cause of cancer death in Western countries\(^\text{[4]}\). More than half of CRC patients will develop metastatic lesions (mCRC), which are often found in the liver\(^\text{[2]}\). Although novel pharmaceutical and surgical interventions have been introduced to treat mCRC, the 5-year survival rate for mCRC remains below 10%\(^\text{[5]}\). Recently cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) has
been proven to be efficacious in mCRC patients\[^{9}\]. Cetuximab binds to EGFR via its ligand-binding domain to inhibit the activation of EGFR signaling. In clinical trials, cetuximab has been reported to achieve a response rate of 10% as a single agent and of 23%-25% in combination with chemotherapy\[^{6,10}\]. The addition of cetuximab to chemotherapies enhances their antitumor activity\[^{11}\]. The proposed mechanisms include: reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points\[^{12}\]. These effects may enhance and restore tumor sensitivity to cytotoxic agents\[^{5}\].

In CRC patients, EGFR is overexpressed in 75% of the tumors and its overexpression is associated with worse outcome\[^{6}\]. EGFR was accordingly an obvious candidate for targeted therapy in this malignancy\[^{13}\]. The tumor suppressor phosphate and tensin homolog (PTEN) is an important negative regulator of cell-survival signaling\[^{14}\]. To date, there is evidence to suggest that loss of expression of PTEN has negative association with the prognosis of CRC, especially mCRC. Loss of PTEN expression results in increased phosphatidylinositol phosphate-3 concentration, which induces subsequent protein kinase B hyperphosphorylation, thus protecting cancer cells from apoptotic stimuli\[^{15,16}\]. In addition, underexpression of PTEN confers resistance to cetuximab-induced apoptosis\[^{17}\].

It is important to reveal the relation between the expression of PTEN and the prognosis of mCRC patients treated with cetuximab, as this will be helpful for adopting appropriate targeted therapy for patients\[^{18}\]. At present, there are many studies which have reported the clinical outcomes of cetuximab in mCRC patients with loss of expression of PTEN. Hence, we carried out a meta-analysis to analyze the relation between the expression of PTEN and prognosis of CRC patients treated with cetuximab.

### MATERIALS AND METHODS

#### Eligibility criteria

The purpose of this research was to systematically review the published articles of cetuximab-based chemotherapy in CRC (both primary and metastatic). Studies which reported the patients’ PTEN status and compared the prognosis, were included in the analysis. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS). Care was taken to include only primary data or data that superseded earlier work.

#### Identification of studies

The search for studies was performed using the electronic database PubMed with the keywords “colorectal cancer”, “cetuximab” and “PTEN”. We also referred to the electronic database ASCO and EMBASE. All studies matching the eligibility criteria were retrieved and their bibliographies were checked for other relevant publications. Review articles and bibliographies of other relevant studies were identified through hand-searching to identify the additional studies. Data from review articles, case reports, abstracts, and letters were not included. Pharmaceutical industries and authors were not contacted. Characteristics of the studies were extracted from published articles and summarized in a consistent manner to aid comparison\[^{19}\].

#### Statistical analysis

The meta-analysis was conducted by using Stata software (version 10.0; StataCorp Lakeway, College Station, TX, United States). Before performing the analyses, data of each published study were carefully checked and verified for coherence with the original publications. The strength of the association between status of PTEN and response of cetuximab-based therapy was measured by the risk ratio (RR) with 95% confidence intervals (CIs). Individual trial level time-to-event data was summarized by the hazard ratio (HR) with 95% CIs. Pooled estimations of RR and HR were obtained by calculating a weighted average of RR and HR from each study.

Statistical heterogeneity between studies was evaluated with the $I^2$ test with significance set at a $P$ value of 0.05. The percentage of total variation across the studies, with higher values indicating a greater degree of heterogeneity, was measured by the $I^2$ statistic. If the $P$ value was $\leq 0.05$, the assumption of homogeneity was deemed invalid, and the DerSimonian-Laird method\[^{20}\] (random-effects model) was used after exploring the causes of the heterogeneity; otherwise, the Mantel-Haenszel method\[^{21}\] (fixed-effects model) was used. In the absence of heterogeneity, the fixed-effects and random-effects models provided similar results. $I^2$ lay between 0% and 100%, and a value of 0% indicated no observed heterogeneity, while larger values indicated increasing heterogeneity\[^{21}\].

Findings of the meta-analysis are depicted in classical Forest plots, with point estimates and 95% CIs for each trial and overall size of the squares proportional to the effect size\[^{19}\]. It was statistically significant when the two-tailed $P$ value $< 0.05$. Publication bias was adjusted using the trim-and-fill method, and assessed by visual inspection of funnel plots (Figure 1)\[^{22}\].

### RESULTS

#### Description of studies

After exclusion of duplicate and irrelevant studies (Figure 2), our search yielded 8 eligible published studies that were retrieved for more detailed evaluation and meta-analysis\[^{13,15,20,23}\]. The main characteristics of these selected studies are summarized in Table 1, and the description of PTEN status listed in Table 2. Most of the patients received a cetuximab-based therapy as second-line or later therapy after chemotherapy failure. All 8 studies including a total of 698 patients, of whom 513 were allocated to cetuximab plus irinotecan and others to cetuximab only or with various regimens as shown in detail in Table 1. The outcome measures of the above studies were evaluated based on the Response Evaluation Criteria in Solid Tu...
mor criteria, PFS and OS. Patients with stable disease or progression of disease were defined as non-responders. Results are presented for the comparisons with the available data.

### Analysis of status of the PTEN homolog and objective response

Five articles documented the response rate of cetuximab-based therapy (Figure 3A). There were 266 patients with loss of PTEN and 496 patients with normal expression of PTEN. In total, compared with 20 of 266 patients with loss of PTEN, 206 of 496 patients with intact protein expression had an objective response rate to cetuximab-based therapy (RR, 4.75; 95% CI, 2.59-8.72; P < 0.001). There was no heterogeneity between trials (P = 0.637, I² = 0.0%). We also analyzed the response to cetuximab-based therapy in metastatic and primary colorectal tumors. Cetuximab-based therapy achieved significantly higher RR among patients with PTEN expression for metastatic tumors (RR, 6.46; 95% CI, 2.94-14.19; P < 0.001). In contrast, among 128 assessable primary tumors, 32 of 87 PTEN-positive and 5 of 41 PTEN-negative patients were

---

### Table 1 The main characteristics of the 8 selected studies

| No. | Title of the study                                                                 | Method     |
|-----|------------------------------------------------------------------------------------|------------|
| 1   | Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer | IHC        |
| 2   | PT3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | FISH       |
| 3   | PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer | IHC        |
| 4   | PTEN status in advanced colorectal cancer treated with cetuximab                    | FISH       |
| 5   | PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | IHC        |
| 6   | PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients | IHC        |
| 7   | Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study | FISH       |
| 8   | Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer | IHC        |

PTEN: Phosphatase and tensin homolog; BRAF: V-raf murine sarcoma viral oncogene homolog; EGFR: Epidermal growth factor receptor; IHC: Immunohistotechnology; FISH: Fluorescence in situ hybridization.

---

### Table 2 Description of phosphatase and tensin homolog status

| No. | Title                                                                 | Method |
|-----|----------------------------------------------------------------------|--------|
| 1   | Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer | IHC    |
| 2   | PT3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | FISH   |
| 3   | PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer | IHC    |
| 4   | PTEN status in advanced colorectal cancer treated with cetuximab     | FISH   |
| 5   | PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | IHC    |
| 6   | PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients | IHC    |
| 7   | Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study | FISH   |
| 8   | Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer | IHC    |

---

### Figure 1 Begg’s funnel plot of publication bias.

![Begg’s funnel plot of publication bias](image1)

### Figure 2 Selection of the studies.

![Selection of the studies](image2)

---
Study of PTEN-positive/NPTEN-negative RR (fixed) Weight 95% CI

01 Primary colorectal cancer
Fotios Loupakis, 2009 11/49 4/36 72.29 2.020 (0.700, 5.834)
FV Negri, 2009 21/38 1/5 27.71 2.763 (0.468, 16.324)
Subtotal (95% CI) 87 41 $\chi^2 = 0.09$, d.f. = 1 ($P = 0.765$), $I^2 = 0.00$
Test for heterogeneity: $\chi^2 = 2.21$, d.f. = 4 ($P = 0.697$), $I^2 = 0.00$
Test for overall effect: $Z = 4.65$ ($P = 0.000$)

02 Metastatic colorectal cancer
Fotios Loupakis, 2009 12/33 1/22 15.56 8.000 (1.119, 57.215)
FV Negri, 2009 14/20 0/4 10.47 6.905 (0.490, 97.254)
Andrea Sartore-Bianchi, 2009 17/49 1/32 15.69 11.102 (1.553, 79.369)
Evangelia Razis, 2008 18/43 3/23 50.69 3.209 (1.055, 9.762)
M Frattini, 2007 10/16 0/11 7.6 14.824 (0.958, 229.366)
Subtotal (95% CI) 161 92 $\chi^2 = 2.21$, d.f. = 4 ($P = 0.697$), $I^2 = 0.00$
Test for heterogeneity: $\chi^2 = 6.462 (2.943, 14.192)
Test for overall effect: $Z = 4.65$ ($P = 0.000$)

Legend: $n$ = Number of responses $N$ = Number of patients

---

Study of HR (fixed) Weight HR (fixed)

01 PFS
Fotios Loupakis, 2009 23/82 5/58 44.06 3.254 (1.314, 8.057)
FV Negri, 2009 35/58 1/9 13.02 5.431 (0.846, 34.874)
Andrea Sartore-Bianchi, 2009 17/49 1/32 9.1 11.102 (1.553, 79.369)
Evangelia Razis, 2008 18/43 3/23 50.69 3.209 (1.055, 9.762)
M Frattini, 2007 10/16 0/11 7.6 14.824 (0.958, 229.366)
Subtotal (95% CI) 248 133 $\chi^2 = 2.54$, d.f. = 4 ($P = 0.637$), $I^2 = 0.00$
Test for heterogeneity: $\chi^2 = 12.93$, d.f. = 1 ($P = 0.002$), $I^2 = 84.5$
Test for overall effect: $Z = 5.02$ ($P = 0.000$)

Legend: $n$ = Number of responses $N$ = Number of patients

---

Study of OS

01 PFS
Fotios Loupakis, 2009 23.05 0.450 (0.120, 0.870)
Andrea Sartore-Bianchi, 2009 76.95 0.770 (0.501, 1.167)
Subtotal (95% CI) 100.00 0.675 (0.473, 0.964)

Test for heterogeneity: $\chi^2 = 1.27$, d.f. = 1 ($P = 0.259$), $I^2 = 21.6$
Test for overall effect: $Z = 2.16$ ($P = 0.031$)

02 OS
Fotios Loupakis, 2009 34.79 0.760 (0.380, 1.430)
Andrea Sartore-Bianchi, 2009 65.21 0.540 (0.332, 0.874)
Subtotal (95% CI) 100.00 0.608 (0.411, 0.899)

Test for heterogeneity: $\chi^2 = 0.67$, d.f. = 1 ($P = 0.414$), $I^2 = 0.0$
Test for overall effect: $Z = 2.49$ ($P = 0.013$)

Legend: $n$ = Number of responses $N$ = Number of patients

---

Shen Y et al. PTEN and cetuximab effects

Figure 3 Analysis of status of the phosphatase and tensin homolog homolog. A: Analysis of status of the phosphatase and tensin homolog (PTEN) homolog and objective response; B: Analysis of status of the PTEN homolog and survival; C: Combined analysis of the PTEN homolog and Kirsten rat sarcoma 2 viral onco-gene homolog (KRAS) status and survival. RR: Risk ratio; CI: Confidence interval; HR: Hazard ratio; OS: Overall survival; PFS: Progression-free survival.
responders, and there was no significant difference observed (RR, 2.226; 95% CI, 0.893-5.348; P = 0.086). There was no evidence for heterogeneity between the studies (P = 0.697, I² = 0%; P = 0.765, I² = 0%; respectively).

Analysis of status of the phosphatase and tensin homolog and survival

Only two trials involving 170 patients were included in this comparison, because none of the other eligibility criteria had sufficient follow-up data listed (Figure 3B). The HR summarizes survival for PTEN-positive compared with PTEN-negative patients after cetuximab-based therapy, with an HR of less than 1 indicating a survival advantage for expression of PTEN in colorectal tumors. As for PFS, PTEN positivity was associated with better survival (HR, 0.675; 95% CI, 0.473-0.964; P = 0.031). The analysis for OS confirmed that loss of PTEN was significantly associated with poor clinical outcome (HR, 0.608; 95% CI, 0.411-0.899; P = 0.013). There was no significant intergroup heterogeneity for the end points of PFS (P = 0.259, I² = 21.6%) or OS (P = 0.414, I² = 0%).

Combined analysis of the PTEN homolog and KRAS status and survival

The studies selected for this analysis are listed in Figure 3C. The HR summarizes survival for PTEN-positive/wtKRAS vs PTEN-negative/wtKRAS, with an HR of less than 1 indicating a survival advantage for PTEN-positive/wtKRAS. Overall, among patients with KRAS wild-type status, PTEN positivity did not predict a longer PFS or OS (PFS: HR, 0.707; 95% CI, 0.440-1.138; P = 0.154; OS: HR, 0.943; 95% CI, 0.646-1.377; P = 0.761). Heterogeneity was not found among trials for the analysis of PFS (P = 0.308, I² = 3.9%). However, there was marked intergroup heterogeneity for the combined analysis of OS making it difficult to obtain a clear conclusion (P = 0.002, I² = 84.5%). To adjust for this bias, the trim-and-fill method was implemented. The adjusted estimates for OS were obtained by using the random-effects model (HR, 0.759; 95% CI, 0.411-0.899; P = 0.013). In the results from the data, there was no difference between the fixed-effects and the random-effects model, indicating the reliability of this meta-analysis, so we can reach a real conclusion.

DISCUSSION

Nowadays, there is a trend towards individualized treatment in tumor therapy. The optimized application of cetuximab has paved a way for individualized treatment of CRC[24]. In recent years, cetuximab has been widely used in the patients with mCRC, and most of the patients have better prognosis than those treated with combined chemotherapy alone. However, personalized cancer medication is based on the genetics of individual colorectal tumors[24]. Hence, the effects of molecular alterations, especially the activating mutations in the KRAS protein, and the corresponding therapeutic effect of cetuximab have been widely discussed[25-27]. KRAS mutation testing is used in the setting of EGFR-targeted therapy for metastatic disease worldwide[29]. Nevertheless, an intact KRAS is necessary but not sufficient to obtain benefit from EGFR inhibition[29,30]. Alterations in other downstream effectors of EGFR, such as BRAF and PIK3CA/PTEN have been found to give rise to cetuximab resistance[1-3]. Therefore, there is a deep need to reveal possible interactions between targeted agents, so that we can better select patients likely to respond to cetuximab-based treatment[29,30,31].

In this study, we focused on the association between the alteration of PTEN protein expression and the therapeutic effects of cetuximab in CRC patients. In addition, patients treated with panitumumab were also listed in the study search, because the two EGFR inhibitors, cetuximab (the chimeric IgG1 monoclonal antibody) and panitumumab (the humanized IgG2 monoclonal antibody), are currently approved in medication for CRC[32,33]. Both of the molecules bind to the EGFR, leading to inhibition of its downstream signaling and providing some clinical benefit.

PTEN is a tumor suppressor protein, which works as a negative regulator of PI3K/PTEN/Akt, which is a cell-survival signaling pathway[36]. Loss of PTEN expression was associated with the aggressive capacity of CRC, and that understanding the biologic mechanisms responsible for regulation of PTEN expression may allow better translational treatment of CRC patients. Furthermore, CRC patients with loss of PTEN expression show resistance to cetuximab[31].

In our selected studies, patients with normal PTEN expression had higher RR in all CRC with cetuximab-based therapy (especially in mCRC). Also we revealed that patients with PTEN normal expression with cetuximab treatment have better prognosis than those without cetuximab treatment and statistical analysis (OS and PFS) also presents significant differences (P < 0.05). In these studies we concluded that PTEN be proposed as an independent predictive factor[3] of cetuximab efficacy. We suggested that PTEN could help to predict prognosis and efficacy of cetuximab. Diagnostic evaluation of PTEN expression might provide additional guidelines for the treatment strategies for CRC patients and valuable prognostic information.

On the other hand, we did a combined analysis of PTEN and KRAS status on OS and PFS. Unfortunately, among patients with wild-type KRAS, PTEN positivity did not predict longer PFS and OS. Only one report showed the interaction between KRAS mutations with or without expression of PTEN in CRC. Thus, we could not perform a meta-analysis. The conclusion obtained in the report was that the PFS and OS of PTEN-positive patients with KRAS mutations were not significantly longer than in all other patients who presented with KRAS mutations and were PTEN-negative[31]. Survival analyses by Loupakis et al[33] demonstrated that BRAF mutations (HR, 3.75; P = 0.015) but not PIK3CA mutations (HR, 1.20; P = 0.672), were significantly associated with decreased OS, whereas neither of these alterations was significantly
associated with PFS. Further clinical data are necessary to identify a certain genes-alteration signature to predict the therapeutic effects of cetuximab-based therapy.

There are some limitations in this meta-analysis. First, the numbers of published studies were not adequate for a comprehensive analysis. Second, only 3 trials reported data of PFS and OS, and a lack of the original data in some studies limited our evaluation of survival, which may cause serious confounding bias. Third, although significant heterogeneity in some end-point variables were at least partly overcome by random-effects analysis, there was still heterogeneity between the relevant studies for inclusion, which may have affected the final results.

In conclusion, our meta-analysis showed an important role of PTEN status in determining the application of cetuximab-based targeted therapy. More clinical trials are warranted in this field to obtain more accurate results. Further improvement in the tailoring of EGFR targeted therapies needs more studies on molecular dissection of the EGFR-initiated oncogenic signaling cascade.

COMMENTS

Background
Cetuximab as a monoclonal antibody (mAb) that has been used in colorectal cancer (CRC) patients. However, the responses vary in different individuals. Phosphatase and tensin homolog (PTEN) is an important negative regulator and its downregulation has been found in many CRC patients. The relationship between PTEN expression and the effects of cetuximab in CRC patients is still uncertain. The aim of this meta-analysis was to obtain a correlation.

Research frontiers
Cetuximab is a mAb that targets the epidermal growth factor receptor (EGFR). It binds to EGFR via its ligand-binding domain to inhibit the activation of EGFR signaling. Cetuximab has been reported to achieve a response rate of 10% as a single agent and of 23%-25% in combination chemotherapy. PTEN is an important negative regulator of cell-survival signaling and underexpression of PTEN confers resistance to cetuximab-induced apoptosis.

Innovations and breakthroughs
Many studies have reported the clinical outcomes of cetuximab in CRC patients with loss expression of PTEN. An exact conclusion has not been achieved as a single agent and of 23%-25% in combination chemotherapy. PTEN is an important negative regulator of cell-survival signaling and underexpression of PTEN confers resistance to cetuximab-induced apoptosis.

Applications
This study may be helpful for adopting appropriate target therapy of cetuximab in patients with CRC.

Terminology
PTEN is the tumor suppressor phosphatase and tensin homolog that plays as an important negative regulator of cell-survival signaling.

Peer review
This is an interesting manuscript presenting a systematic analysis of the impact of PTEN expression on CRC response to cetuximab. It has clear limitations due to the quality of published papers. However, its findings are interesting.

REFERENCES
1 Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, Wakasugi T, Takahashi H, Funahashi H, Sato M, Takeyama H. Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 2008; 8: 56
2 Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lerdick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Strosczyznski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
3 Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nicolotti M, Artale S, Di Nicolantonio F, Saletti F, De Dosso S, Mazuccchelli L, Frattini M, Siena S, Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857
4 Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634
5 Negri FV, Bossi C, Lagrasta CA, Kraut P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A. PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 2010; 102: 162-164
6 Hebb bar M, Warrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17: 855-857
7 Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, Bleuse JP, Ychou M. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for untreated metastatic colorectal cancer: a phase II trial. Oncologist 2011; 16: 1557-1564
8 Gerber DE, Choy H. Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev 2010; 29: 171-180
9 Laurent-Puig P, Cayre A, Manceau G, Bac E, Bachet JB, Lemutte T, Rouger F, Lievre A, Landi B, Boige V, Ducrues X, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colorectal cancer. J Clin Oncol 2009; 27: 5924-5930
10 Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestri E, Funel N, Schiavon G, Petruini I, Magnani M, Tonini G, Campani D, Floriani I, Cascini S, Falcone A. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-2629
11 Van Cutsem E, Köhne CH, Hittre E, Zaluski J, Chang Chien CR, Makhton A, D’Haens G, Pintet T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruft P, Stroob C, Teijpar S, Schlimching M, Nippgen J, Rouger P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
12 Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390
13 Moroni F, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286
14 Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529-536
15 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
16 Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 341-350
17 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
18 Ibrahim EM, Zekri JM, Bin Sadiq BM. Cetuximab-based...
therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. *Int J Colorectal Dis* 2010; 25: 713-721
19 Song F, Gilbody S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. *BMJ* 1998; 316: 471
20 Eralhini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. *Br J Cancer* 2007; 97: 1139-1145
21 Perrone E, Lampis A, Orsengo M, Di Bartolomeo M, Gegovyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Piloti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Ann Oncol* 2009; 20: 84-90
22 Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichail D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P, Fountzilas G. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. *BMC Cancer* 2008; 8: 234
23 Sartore-Bianchi A, Di Nicolantonio F, Michelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibody with activity in metastatic colorectal cancer. *PLoS One* 2009; 4: e7287
24 Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *J Clin Oncol* 2010; 28: 1254-1261
25 Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. Colorectal cancer: mutations in a signalling pathway. *Nature* 2005; 436: 792
26 Li FH, Shen L, Li ZH, Luo HY, Quo MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. *World J Gastroenterol* 2010; 16: 8881-8888
27 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. *Int J Colorectal Dis* 2011; 26: 823-833
28 De Rook W, Biesmans B, De Schutter J, Teijpar S. Clinical biomarkers in oncology: focus on colorectal cancer. *Mol Diagn Ther* 2009; 13: 103-114
29 Silvestris N, Tonnmai S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E, Colucci G. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. *Oncology* 2009; 77 Suppl 1: 69-74
30 Meriggi F, Di Biasi B, Abeni C, Zaniboni A. Anti-EGFR therapy in colorectal cancer: how to choose the right patient. *Curr Drug Targets* 2009; 10: 1033-1040
31 Bouchahda M, Karaboué A, Saffroy R, Innominato P, Gordon L, Geurrier C, Adam R, Levi F. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. *Cancer Chemother Pharmacol* 2010; 66: 605-609
32 Moosmann N, von Weikerthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzelbinger H, Oruzo D, Klein S, Zellmann K, Decker T, Schulze M, Abenhart W, Puchler G, Kappauf H, Mittermüller J, Haberl C, Schallhorn A, Jung A, Stintzing S, Heinemann V. Cetuximab plus capcitabine and irinotecan compared with cetuximab plus capcitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. *J Clin Oncol* 2011; 29: 1050-1058
33 Souglakos J, Philips J, Wang R, Marwha S, Silver M, Tzardi M, Silver J, Ogin S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulas V, Finkelstein D, Fuchs CS, Kulke MH, Shvidlarz SM. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. *Br J Cancer* 2009; 101: 465-472
34 Ortega J, Vigil CE, Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. *Cancer Control* 2010; 17: 7-15
35 Saadeh CE, Lee HS. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. *Ann Pharmacother* 2007; 41: 606-613
36 Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, Lee SJ, Jeon SW, Park JS, Park YJ, Choi GS. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. *Oncology* 2010; 79: 279-282

S- Editor: Gou SX  L- Editor: Cant MR  E- Editor: Xiong L